MRK stock verdict - Avoid
MRK
Merck & Co., Inc.
AVOIDHealthcare
$148.78
Fundamentals below bar
$148.78
Heavy$80.70Buy$107.60Fair$134.50Exit$161.40
VALUE34
GROWTH18
QUALITY82
TECHNICAL—
TRUST SCORE
96High
confidence in this read — data completeness, earnings quality & coverage
Technicals: insufficient price history
PROS
- Balance sheet holds net cash (cash exceeds total debt)
- Converts 24% of revenue into free cash flow
- High gross margin of 75% (3-yr avg)
CONS
- Expensive on trailing earnings (P/E 115.7×)
- Rich for its growth rate (PEG 3.1)
- Company has a low return on equity of 7.6% (TTM)
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 629% of net income — profit is backed by real cash
Analysis as of 2026-09-25 · price live, fundamentals from latest filings
Congress Trading — last 90 days
See what senators are buying and selling on MRK. Sign in to unlock.
📊 Options Flow — Put/Call Ratio
FAQ
Why is MRK rated Avoid?
MRK (Merck & Co., Inc.) is rated Avoid because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Fundamentals below bar. Balance sheet holds net cash (cash exceeds total debt) and Converts 24% of revenue into free cash flow
Is MRK overvalued right now?
MRK is trading at $148.78 versus an estimated fair value of $134.50. That puts the stock in avoid territory on this framework. Expensive on trailing earnings (P/E 115.7×) and Rich for its growth rate (PEG 3.1)
What should I watch before acting on MRK?
Watch the trust score of 96, the earnings-quality checks, and any red flags. Expensive on trailing earnings (P/E 115.7×) and Rich for its growth rate (PEG 3.1)